HPTN 074

Integrated treatment and prevention for people who inject drugs: an innovative, randomized, networked HIV prevention study comparing an integrated model of providing antiretroviral therapy with a standard of care.

Responsible executors: HIV Prevention Trials Network (HPTN) and the U.S. National Institutes of Health (NIH), Bethesda, MD, USA, Ukrainian Institute for Public Health Policy Research, Yenei Club, Institute of Epidemiology and Infectious Diseases named after. LV Gromashevsky of the National Academy of Sciences of Ukraine “

Research sponsors: NIH, Division of AIDS (DAIDS), US National Institute of Allergy and Infectious Diseases (NIAID) and US National Institute on Drug Abuse (NIDA), Bethesda, MD, USA.

The purpose of this study is: The aim of this study is to develop a new, improved method for preventing the spread of HIV (human immunodeficiency virus, the virus that causes AIDS) among people who use injecting drugs. This study is funded by the National Institutes of Health; the study is conducted in Kiev (Ukraine) by the Ukrainian Institute for Public Health Policy Research (UIIPOZ)

All this information will help to develop a future study that will help determine whether treatment of HIV-infected injecting drug users with antiretroviral drugs and the provision of other support services, including substitution therapy where available, will help prevent their HIV transmission to their partners in injecting drug use